Oryzon Genomics Balance Sheet Health
Financial Health criteria checks 5/6
Oryzon Genomics has a total shareholder equity of $77.7M and total debt of $24.0M, which brings its debt-to-equity ratio to 30.9%. Its total assets and total liabilities are $111.0M and $33.3M respectively.
Key information
30.9%
Debt to equity ratio
US$24.03m
Debt
| Interest coverage ratio | n/a |
| Cash | US$22.83m |
| Equity | US$77.71m |
| Total liabilities | US$33.33m |
| Total assets | US$111.04m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ORY N's short term assets ($26.9M) exceed its short term liabilities ($20.1M).
Long Term Liabilities: ORY N's short term assets ($26.9M) exceed its long term liabilities ($13.3M).
Debt to Equity History and Analysis
Debt Level: ORY N's net debt to equity ratio (1.5%) is considered satisfactory.
Reducing Debt: ORY N's debt to equity ratio has reduced from 67.9% to 30.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ORY N has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ORY N has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.